Valeant Pharmaceuticals International, Inc. (NYSE:VRX)

Valeant Pharmaceuticals International, Inc. is a pharmaceutical company that develops, manufactures and markets a broad range of pharmaceutical products primarily in the areas of neurology, dermatology and branded generics. The Company produces medicines that meet the special health problems of patients. Valeant’s development pipeline strategy comprises both new compounds as well as product life cycle management. Its early and late-stage drug candidates have unique formulations and mechanisms of action including retigabine for the treatment of epilepsy and pain, taribavirin of the treatment of chronic hepatitis C, and several dermatology candidates for the treatment of rosacea, acne, and dermatological fungus. Valeant Pharmaceuticals International, Inc. is headquartered in Mississauga, Canada.

Valeant Pharmaceuticals International, Inc. (NYSE:VRX)’s Financial Overview

Valeant Pharmaceuticals International, Inc. (NYSE:VRX) declined -1.61% yesterday to close its trading session at $17.16. The company has 1 year Price Target of $24.66. Valeant Pharmaceuticals International, Inc. has 52-Week high of $119.87 and 52-Week Low of $13.77. The stock touched its 52-Week High on Dec 16, 2015 and 52-Week Low on Nov 8, 2016. The stock traded with the volume of 8.08 Million shares yesterday. The firm shows the market capitalization of $5.86 Billion.

Valeant Pharmaceuticals International, Inc. (NYSE:VRX) reported its last quarterly earnings on Sep 16 where the firm reported its Actual EPS of $1.55/share against the analyst consensus estimate of $1.75/share. The difference between the actual and expected EPS is $-0.2 a share with a surprise factor of -11.4%.

The firm is trading with SMA20 of -5.57 Percent, SMA50 of -20.4 Percent and SMA200 of -44.09 percent. Valeant Pharmaceuticals International, Inc. has P/S value of 0.59 while its P/B value stands at 1.44. Similarly, the company has Return on Assets of -4.7 percent, Return on Equity of -42.9 percent and Return on Investment of 3.7 Percent. The company shows Gross Margin and Operating Margin of 73.8 percent and -5.2 percent respectively.

Many brokerage firms are involved in issuing their ratings on Valeant Pharmaceuticals International, Inc. (NYSE:VRX). On 23-Nov-16 Mizuho Downgrade Valeant Pharmaceuticals International, Inc. Stock  to Underperform. Another firm also rated the stock on 10-Nov-16 where Rodman & Renshaw Downgrade the stock to Neutral.

The Stock currently has Analyst’ mean Recommendation of 2.9 where the scale is from 1 to 5, 1 means Strong Buy and 5 means Sell.

The 19 analysts offering 12-month price forecasts for Valeant Pharmaceuticals have a median target of 23.00, with a high estimate of 55.00 and a low estimate of 9.00. The median estimate represents a +34.03% increase from the last price of 17.16.

Our vendor, Zacks Investment Research, hasn’t provided us with the upcoming earnings report date.

Brocade Communications Systems, Inc. (NASDAQ:BRCD)

Brocade Communications Systems, Inc. delivers industry-leading platforms, solutions, and services for intelligently connecting, managing, and optimizing IT resources in shared storage environments. The world’s premier systems, server, and storage providers offer the Brocade SilkWorm family of Storage Area Network connectivity platforms as the foundation for shared storage in organizations of all sizes. In addition, the Brocade Tapestry family of IT infrastructure solutions extends the ability to proactively manage and optimize application and information resources across the enterprise. Using Brocade solutions, organizations are better positioned to reduce cost, manage complexity, and satisfy business compliance requirements through optimized use and management of their IT resources.

Brocade Communications Systems, Inc. (NASDAQ:BRCD)’s Financial Outlook

Brocade Communications Systems, Inc. is estimated to report earnings on  11/29/2016. The upcoming earnings date is derived from an algorithm based on a company’s historical reporting dates.Our vendor, Zacks Investment Research, might revise this date in the future, once the company announces the actual earnings date. According to Zacks Investment Research, based on 2 analysts’ forecasts, the consensus EPS forecast for the quarter is $0.21.  The reported EPS for the same quarter last year was $0.24.

According to Zacks Investment Research, Brocade Communications Systems, Inc. has a Consensus Recommendation of 3.27. (The Scale is from 1-5 where 1 means Strong Buy and 5 means Strong Sell).

The Stock fell -0.32% and closed its last trading session at $12.36. The company has the market capitalization of $4.95 Billion. The stock has 52-week high of $12.5 and 52-Week low of $7.4. The firm touched its 52-Week high on Nov 25, 2016 and 52-Week low on Jan 20, 2016. The company has volume of 7.98 Million shares. The company has a total of 400.87 Million shares outstanding.

Brocade Communications Systems, Inc. (NASDAQ:BRCD) in the last quarter reported its actual EPS of $0.33/share where the analyst estimated EPS was $0.22/share. The difference between the actual and Estimated EPS is $0.11. This shows a surprise factor of 50 percent.

The company has YTD performance of 36.9 percent. Beta for Brocade Communications Systems, Inc. stands at 0.92 while its ATR (average true range) is 0.21. The company has Weekly Volatility of 0.74%% and Monthly Volatility of 2.41%%.

Brocade Communications Systems, Inc. has distance from 20-day Simple Moving Average (SMA20) of 1.25%, Distance from 50-Day Simple Moving Average of 20.18 percent and Distance from 200-Day Simple Moving Average of 29.99%.

The Company currently has ROA (Return on Assets) of 4.8 percent, Return on Equity (ROE) of 8.5 Percent and Return on Investment (ROI) of 6.3% with Gross margin of 64.6 percent and Operating & Profit margin of 13.1% and 9.1% respectively.